Peptide and Peptidomimetic Inhibitors of Smoothened Protein as Anti-neoplastic Agents
Posted Jun 09 2010 5:00pm
Description of Invention: Cancer is caused by the improper regulation of certain signaling proteins in the cell. One of these pathways is the Hedgehog/Patched (HH/PTCH) pathway. Hedgehog is a secreted protein involved in the growth and development of embryonic cells. Patched is the receptor for hedgehog proteins and regulates a membrane protein called Smoothened (SMO). This pathway is activated in many tumor cells, including those in prostate, pancreas, stomach, and small cell cancer.
The technology is directed towards several synthetic peptides (including all-D analogs) corresponding to specific region of the SMO protein. Experiments in vitro demonstrate that they potentially suppress the growth of cancer cells and inhibit the expression of the HH/PTCH pathway genes. These novel SMO inhibitors are much more effective in inhibiting cell growth than currently available cyclopamine and cyclopamine derivatives. These novel peptides and their metabolically more stable analogs have a high potential for cancer therapy. Due to their high hydrophobic properties, these can be easily formulated for specific intratumor delivery or topical creams for skin disorders.
A potent, highly soluble cancer therapeutic
Novel compounds that inhibit HH/PTCH pathway genes
Skin permeable compounds that can be formulated into tropical creams for skin malignancies treatment and prevention and treatment of psoriasis
Development Status: The technology is currently in the pre-clinical stage of development.
L Covic et al. Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc Natl Acad Sci USA. 2002 Jan 22;99(2):643-648. [ PubMed abs ]
Licensing Status: Available for licensing.
Collaborative Research Opportunity: The NCI-Frederick Structural Biophysics Laboratory is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Peptide and Peptidomimetic Inhibitors of Smoothened Protein as Anti-neoplastic Agents. Please contact John Hewes, Ph.D., at 240-482-3453 for more information.
Portfolios: Cancer Cancer - Therapeutics Cancer - Research Materials Internal Medicine Internal Medicine - Therapeutics In-vitro Data
For Additional Information Please Contact: Jennifer Wong NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-4633 Fax: 301-402-0220